134 related articles for article (PubMed ID: 11258791)
1. A murine B cell lymphoma expressing human HER2 / neu undergoes spontaneous tumor regression and elicits antitumor immunity.
Penichet ML; Dela Cruz JS; Challita-Eid PM; Rosenblatt JD; Morrison SL
Cancer Immunol Immunother; 2001 Feb; 49(12):649-62. PubMed ID: 11258791
[TBL] [Abstract][Full Text] [Related]
2. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
[TBL] [Abstract][Full Text] [Related]
3. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice.
Penichet ML; Challita PM; Shin SU; Sampogna SL; Rosenblatt JD; Morrison SL
Lab Anim Sci; 1999 Apr; 49(2):179-88. PubMed ID: 10331548
[TBL] [Abstract][Full Text] [Related]
4. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
5. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
Neeson P; Pan ZK; Paterson Y
Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
[TBL] [Abstract][Full Text] [Related]
6. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities.
Huang TH; Chintalacharuvu KR; Morrison SL
J Immunol; 2007 Nov; 179(10):6881-8. PubMed ID: 17982079
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
Kwak LW; Young HA; Pennington RW; Weeks SD
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
[TBL] [Abstract][Full Text] [Related]
8. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
Weiner GJ; Hillstrom JR
J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
[TBL] [Abstract][Full Text] [Related]
9. The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma.
Singh G; Parker S; Hobart P
Vaccine; 2002 Jan; 20(9-10):1400-11. PubMed ID: 11818159
[TBL] [Abstract][Full Text] [Related]
10. Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.
Weiner GJ; Kaminski MS
J Immunol; 1990 Mar; 144(6):2436-45. PubMed ID: 1690244
[TBL] [Abstract][Full Text] [Related]
11. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.
Kaminski MS; Kitamura K; Maloney DG; Levy R
J Immunol; 1987 Feb; 138(4):1289-96. PubMed ID: 3492546
[TBL] [Abstract][Full Text] [Related]
12. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro.
Maloney DG; Kaminski MS; Burowski D; Haimovich J; Levy R
Hybridoma; 1985; 4(3):191-209. PubMed ID: 3899906
[TBL] [Abstract][Full Text] [Related]
14. Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu.
Baral R; Sherrat A; Das R; Foon KA; Bhattacharya-Chatterjee M
Int J Cancer; 2001 Apr; 92(1):88-95. PubMed ID: 11279611
[TBL] [Abstract][Full Text] [Related]
15. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
16. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin.
Kwak LW; Campbell MJ; Zelenetz AD; Levy R
Blood; 1990 Dec; 76(11):2411-7. PubMed ID: 2257310
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo.
Franki SN; Steward KK; Betting DJ; Kafi K; Yamada RE; Timmerman JM
Blood; 2008 Feb; 111(3):1504-11. PubMed ID: 17993615
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
19. Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma.
Weiner GJ; Kaminski MS
J Immunol; 1989 Jan; 142(1):343-51. PubMed ID: 2783325
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
